ArticleCirculation research2016
Resolving Lipid Mediators Maresin 1 and Resolvin D2 Prevent Atheroprogression in Mice.
Open access · bronzeAbstract read
In one paragraph
Article in Circulation research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 149 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
149citing papers in PubMed, 3 pooled it
16.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
149 citing papers in PubMed, 3 syntheses or guidelines pooled it, 221 citations in OpenAlex.
- Sex Differences in Omega-3 and Omega-6 PUFA Status: A Systematic Review and Meta-analysis of Cross-Sectional Comparisons.Advances in nutrition (Bethesda, Md.) · 2026Pooled it
- Maresin: Macrophage Mediator for Resolving Inflammation and Bridging Tissue Regeneration-A System-Based Preclinical Systematic Review.International journal of molecular sciences · 2023Pooled it
- Role of long-chain polyunsaturated fatty acids, eicosapentaenoic and docosahexaenoic, in the regulation of gene expression during the development of obesity: a systematic review.Frontiers in nutrition · 2023Pooled it
- Lipoxins modulate neutrophil oxidative burst, integrin expression and lymphatic transmigration differentially in human health and atherosclerosis.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022Trial
- Treatment With a Marine Oil Supplement Alters Lipid Mediators and Leukocyte Phenotype in Healthy Patients and Those With Peripheral Artery Disease.Journal of the American Heart Association · 2020Trial
- The Association of Free Fatty Acids and Eicosanoids with the Severity of Depressive Symptoms in Stroke Patients.International journal of molecular sciences · 2020Trial
- Deficiency of protein kinase Cδ reprograms macrophage immunometabolism to suppress pyroptosis and stabilize atherosclerotic plaques.Experimental & molecular medicine · 2026Article
- The Role of Immunoresolvents in Atherosclerosis: A Mini-Review on Their Biology and Therapeutic Opportunities.Health science reports · 2026Article
- G protein-coupled receptors and inflammation resolution signaling networks in the heart: Pharmacology and potential for innovative therapeutics.Pharmacological reviews · 2026Review
- GPR18 Deletion in Mice Inversely Affects Vasoactive Signaling and Passive Biomechanical Properties of the Thoracic Aorta and Femoral Artery.International journal of molecular sciences · 2026Article
- Maresins.Biomolecules · 2026Review
- Pro-resolving lipid mediators in diseases: exploring the molecular basis and clinical implication.Molecular biomedicine · 2026Review
- Inflammation and Resolution in Obesity-Related Cardiovascular Disease.International journal of molecular sciences · 2026Review
- Microbiota and lipid mediators: from molecular crosstalk to therapeutic opportunities.Frontiers in pharmacology · 2026Review
- Inflammation-resolution signalling in cardiac repair, remodelling, and heart failure.European heart journal open · 2025Review
- Potential and Future Therapeutic Applications of Eicosapentaenoic/Docosahexaenoic Acid and Probiotics in Chronic Low-Grade Inflammation.Biomedicines · 2025Review
- Resolvin D2 limits senescent cell accumulation in atherosclerotic plaques.Vascular pharmacology · 2025Article
- Anti-Atherogenic Mechanisms and Therapies.Current atherosclerosis reports · 2025Review
- Specialized Pro-Resolving Mediators as Emerging Players in Cardioprotection: From Inflammation Resolution to Therapeutic Potential.Acta physiologica (Oxford, England) · 2025Review
- Linking Lipid Metabolism and Immune Function: New Insights into Chronic Respiratory Diseases.Pathophysiology : the official journal of the International Society for Pathophysiology · 2025Review
89 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
14 authors at 3 institutions in 2 countries.
Joana R ViolaFrom the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.).
Patricia LemnitzerFrom the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.).
Yvonne JansenFrom the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.).
Gergely CsabaFrom the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.).
Carla WinterFrom the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.).
Carlos NeideckFrom the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.).
Carlos Silvestre-RoigFrom the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.).
Gunnar DittmarFrom the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.).
Yvonne DöringFrom the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.).
Maik DrechslerFrom the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.).
Christian WeberFrom the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.).
Ralf ZimmerFrom the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.).
Nicolas CenacFrom the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.).
Oliver SoehnleinFrom the Institute for Cardiovascular Prevention (IPEK), LMU Munich, Germany (J.R.V., P.L., Y.J., C.W., C.N., C.S.-R., Y.D., M.D., C.W., O.S.); Department of Pathology, Academic Medical Center (AMC), Amsterdam University, The Netherlands (J.R.V., C.S.-R., M.D., O.S.); Department of Informatics, Institute of Bioinformatics, LMU Munich, Germany (G.C., R.Z.); DZHK, Partner Site Munich Heart Alliance, Germany (C.W., Y.D., M.D., C.W., O.S.); Mass Spectrometry Core Facility, Max-Delbrück Center, Berlin Institute of Health, Germany (G.D.); and Inserm U1043, CHU Purpan, Toulouse, France (N.C.). oliver.soehnlein@gmail.com.
Institute of Bioinformatics and Systems Biology · DEAcademic Medical Center · NLLudwig-Maximilians-Universität München · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
rationaleAtheroprogression is a consequence of nonresolved inflammation, and currently a comprehensive overview of the mechanisms preventing resolution is missing. However, in acute inflammation, resolution is known to be orchestrated by a switch from inflammatory to resolving lipid mediators. Therefore, we hypothesized that lesional lipid mediator imbalance favors atheroprogression.
objectiveTo understand the lipid mediator balance during atheroprogression and to establish an interventional strategy based on the delivery of resolving lipid mediators. METHODS AND
resultsAortic lipid mediator profiling of aortas from Apoe
conclusionsWe present evidence for the imbalance between inflammatory and resolving lipid mediators during atheroprogression. Delivery of RvD2 and MaR1 successfully prevented atheroprogression, suggesting that resolving lipid mediators potentially represent an innovative strategy to resolve arterial inflammation.
Indexed as
AnimalsAtherosclerosisCells, CulturedDiet, High-FatDisease ProgressionDocosahexaenoic AcidsDrug Delivery SystemsInflammation MediatorsLipid MetabolismMiceMice, Inbred C57BLMice, Knockout7,14-dihydroxydocosa-4,8,10,12,16,19-hexaenoic acidDocosahexaenoic AcidsInflammation Mediatorsresolvin D2atherosclerosiscollagenhigh-fat dietinflammationmacrophages
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.